r1507 + cetuximab + irinotecan

A **combination regimen** consisting of three agents: - **R1507** is a fully human monoclonal antibody targeting the insulin-like growth factor 1 receptor (**IGF-1R**), which mediates tumor cell growth and protects against apoptosis[1][2][3][4][5]. Its mechanism involves high-affinity binding to IGF-1R, resulting in blockade of IGF-I dependent signaling, receptor internalization, and downregulation. - **Cetuximab** is a monoclonal antibody that blocks the epidermal growth factor receptor (**EGFR**), preventing ligand-dependent activation and downstream signaling crucial for tumor cell proliferation and survival. - **Irinotecan** is a small molecule chemotherapy agent, a topoisomerase I inhibitor that causes DNA damage and tumor cell death by preventing DNA uncoiling during replication. This combination represents a strategy to simultaneously target multiple key oncogenic pathways, typically employed in advanced solid tumor or colorectal cancer settings. R1507’s further development was discontinued after phase II; cetuximab and irinotecan are approved for various cancers.

Brand names

Campto

Other names

r1507r-1507r 1507cetuximabirinotecanErbituxCampto